A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
A phase 1/2 trial of AK117, Carboplatin, Cisplatin and Gemcitabine in advanced solid tumours, run by Akeso, active and no longer recruiting.
Overview
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors is a phase 1/2 interventional study registered as NCT05229497 by Akeso, with 154 participants enrolled, started 2022-05-04 and due to reach its primary completion in 2026-12-31. Interventions recorded: AK112, AK117, Carboplatin, Cisplatin, 5-Fluorouracil and Gemcitabine.
Similar pages
not linked directly; found by shared links- TrialA Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer
- TrialA Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
Shares Cisplatin, Carboplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia
- TrialPhase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Shares Gemcitabine, Cisplatin, Carboplatin and the tag pipeline.
- Trial9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Shares Gemcitabine, Cisplatin, Carboplatin and the tag pipeline.
- TrialAK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
Shares Akeso, Gemcitabine, Cisplatin and the tag pipeline.
- TrialA Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors
Shares Akeso, Metastatic cancer (cancer that has spread) and the tag pipeline.